CervoMed (NASDAQ:CRVO) is advancing an oral drug candidate, neflamapimod, for neurodegenerative diseases, with its lead focus on dementia with Lewy bodies (DLB), executives said during a Roth Capital Partners discussion. Matt Winton, the company’s Chief Commercial Officer and Chief Business Officer, said he recently returned from the Alzheimer’s and Parkinson’s Disease Conference (AD/PD) in Copenhagen, where CervoMed presented data released in recent weeks and received what he characterized as “overwhelmingly positive” feedback from clinicians and researchers.
DLB described as a large and under-served market
Winton described DLB as one of the largest unmet needs in neurodegeneration, noting it is the second most common progressive dementia after Alzheimer’s disease. He said DLB affects millions worldwide, including more than 700,000 patients in the U.S. Patients typically experience a combination of cognitive decline, fluctuating attention, sleep disorders, visual hallucinations, and Parkinson’s-like motor deficits.
On diagnosis, Winton said DLB is generally managed by neurologists and can be identified using well-defined clinical criteria, with about 90% confirmation at autopsy when those criteria are met. However, he said diagnosis remains underutilized, estimating that only about 50% of DLB patients currently receive a clinical diagnosis.
Neflamapimod’s mechanism centers on p38α inhibition
Winton said neflamapimod is a potent and specific p38α inhibitor that is also highly blood-brain barrier penetrant. He noted the compound was originally developed by Vertex for rheumatoid arthritis, but its central nervous system penetration made it more suitable for neurodegenerative indications.
He described p38α as a stress-activated kinase implicated across multiple neurodegenerative diseases, including DLB, Alzheimer’s, and ALS. In DLB, Winton said the accumulation of misfolded alpha-synuclein (Lewy bodies) can trigger neuroinflammation, further activating p38α and perpetuating a cycle that contributes to neuronal dysfunction. He outlined a downstream pathway involving Rab5 that can impair cellular transport, reduce acetylcholine release, interfere with nerve growth factor signaling, and ultimately drive synaptic dysfunction—a key contributor to DLB symptoms.
CervoMed’s thesis, he said, is that early-stage “pure” DLB (DLB without Alzheimer’s co-pathology) is marked by a potentially reversible functional deficit rather than extensive cell death, creating an opportunity to improve outcomes by restoring synaptic function.
Clinical results and a manufacturing-related setback in Phase IIb
Winton summarized earlier clinical work, stating the company’s Phase IIa study showed improvements in:
- CDR-Sum of Boxes (CDR-SB), which he called a gold-standard cognition scale used in DLB and Alzheimer’s
- Functional tests
- GFAP (glial fibrillary acidic protein), a biomarker associated with neurodegeneration
In the company’s Phase IIb study (159 patients, placebo-controlled for 16 weeks), Winton said the placebo-controlled portion did not show significant results. He attributed the outcome to a manufacturing issue that resulted in lower-than-expected plasma drug concentrations.
He said a second drug batch introduced during the open-label extension achieved targeted concentrations. Using that batch, the company reported significant improvements on CDR-SB and the clinician-rated CGIC, along with a 50% reduction in plasma GFAP when comparing across batches. Winton said these findings increased confidence that clinical effects are tied to achieving adequate plasma exposure.
Phase III plan: one trial, 300 patients, and biomarker-based enrollment
Winton said CervoMed presented its data package to the FDA late last year and received agreement on a Phase III design and what he described as a potential registration path. The planned trial is a single Phase III study enrolling 300 patients over 32 weeks, with CDR-SB as the primary endpoint and progression plus biomarkers as secondary or exploratory endpoints. The company expects to start the study by the end of this year and said it has also received alignment from other global regulators.
Enrollment will focus on DLB patients without Alzheimer’s co-pathology. Winton cited work using plasma pTau181 to enrich for “pure DLB,” estimating that a cutoff could produce 80%–90% enrichment. He said AD/PD data showed a stepwise improvement in drug response as pTau181 levels became lower and more stringent.
When asked about market size under this approach, Winton estimated that literature suggests a roughly 50/50 split between DLB with and without Alzheimer’s co-pathology, translating to about 360,000 U.S. patients without co-pathology, plus over 400,000 in Europe and roughly 300,000 in Asia and parts of Japan. He argued that even a biomarker-targeted subset represents a substantial commercial opportunity, and said payer interest in precision medicine may support value-based pricing.
Dose and formulation updates; additional pipeline readouts expected
Winton said the company has selected a 50 mg three-times-daily (TID) dose for Phase III, up from 40 mg used in Phase IIb. He also said CervoMed updated its manufacturing process and identified a new stable crystal form intended to resolve the prior batch-related exposure issue. He noted animal and Phase I bioavailability studies indicated similar PK/PD profiles versus the efficacious batch used in the extension phase, and said the company does not expect additional safety events based on what he described as clean safety in Phase II.
Beyond DLB, Winton highlighted several additional programs with upcoming milestones:
- Post-stroke recovery (targeting neuroinflammation and synaptic function starting 48 hours post-infarct): data expected by year-end
- Primary progressive aphasia (a subtype within frontotemporal disorders): clinical or biomarker data expected by mid-year
- ALS: CervoMed said it was selected for the U.K.-supported ExPALS program, which evaluates therapies across motor neuron centers and generates biomarker data to support development
The discussion concluded with management reiterating confidence that manufacturing and biomarker-enrollment strategies have “de-risked” the lead program ahead of the planned Phase III initiation.
About CervoMed (NASDAQ:CRVO)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.
